Xarelto Cuts CV Mortality in Stable Coronary, Peripheral Disease | MedPage Today
عبدالله خربوش on X: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial | Journal of the American College of Cardiology
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD | SpringerLink
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC
Stroke Outcomes in the COMPASS Trial | Circulation
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin - ScienceDirect
COMPASS : Rivaroxaban + aspirine chez le vasculaire
COMPASS | Xarelto Global
Rivaroxaban Shows Superiority Over Aspirin in Patients With Coronary and Peripheral Artery Disease | DAIC
COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease | tctmd.com
Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist | Journal of CLI
The COMPASS Trial | Circulation
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial | Journal of the American College of Cardiology
XARELTO (RIVAROXABAN) and COMPASS: Trial halted early due to "overwhelming evidence" of efficacy - YouTube
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
Épisode 10 : Étude COMPASS - BaladoCritique : Club de lecture médical - Université de Sherbrooke
COMPASS-CABG
COMPASS study of Janssen's rivaroxaban to end early for efficacy - 526 Fulham Rd, Fulham, London SW6, UK
COMPASS: Clinical Trial - Post Revascularization & Chronic PAD | XARELTO® ( rivaroxaban) HCP
COMPASS study of rivaroxaban to end early for efficacy - Cardiovascular News
